ACS chemical neuroscience molecule spotlight on RG1678

Corey R. Hopkins

doi:10.1021/cn200108z

ACS chemical neuroscience molecule spotlight on RG1678

Corey R. Hopkins

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

Original language	English (US)
Pages (from-to)	685-686
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	2
Issue number	12
DOIs	https://doi.org/10.1021/cn200108z
State	Published - Dec 21 2011
Externally published	Yes

Keywords

GlyT1
RG1678
Schizophrenia
glycine transporter-1 inhibitor
negative symptoms

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn200108z

Cite this

@article{efd2f4694d8345bca92747efe98ff428,

title = "ACS chemical neuroscience molecule spotlight on RG1678",

abstract = "RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.",

keywords = "GlyT1, RG1678, Schizophrenia, glycine transporter-1 inhibitor, negative symptoms",

author = "Hopkins, {Corey R.}",

year = "2011",

month = dec,

day = "21",

doi = "10.1021/cn200108z",

language = "English (US)",

volume = "2",

pages = "685--686",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "12",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on RG1678

AU - Hopkins, Corey R.

PY - 2011/12/21

Y1 - 2011/12/21

N2 - RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

AB - RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

KW - GlyT1

KW - RG1678

KW - Schizophrenia

KW - glycine transporter-1 inhibitor

KW - negative symptoms

UR - http://www.scopus.com/inward/record.url?scp=84555177567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555177567&partnerID=8YFLogxK

U2 - 10.1021/cn200108z

DO - 10.1021/cn200108z

M3 - Article

C2 - 22860161

AN - SCOPUS:84555177567

SN - 1948-7193

VL - 2

SP - 685

EP - 686

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 12

ER -

ACS chemical neuroscience molecule spotlight on RG1678

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this